A critical role for p130 Cas in the progression of pulmonary hypertension in humans and rodents

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 7, 2012, Pages 666-676

  Tu, Ly ^a,b   De Man, Frances S ^a,b,c   Girerd, Barbara ^a,b,d   Huertas, Alice ^a,b,d   Chaumais, Marie Camille ^a,b   Lecerf, Florence ^a,b   François, Charlène ^a,b   Perros, Fréd́eric ^a,b   Dorfmul̈ler, Peter ^a,b   Fadel, Elie ^a,b   Montani, David ^a,b,d   Eddahibi, Saadia ^a,b   Humbert, Marc ^a,b,d   Guignabert, Christophe ^a,b  

^a CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d BICÊTRE HOSPITAL   (France)

Author keywords

BCAR1; Growth factors; Pulmonary arterial hypertension; Pulmonary vascular remodeling; Signal transduction

Indexed keywords

ADAPTOR PROTEIN; CRK ASSOCIATED SUBSTRATE PROTEIN; DOVITINIB; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GEFITINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 3; 4 AMINO 5 FLUORO 3 (5 (4 METHYLPIPERAZIN 1 YL) 1H BENZIMIDAZOL 2 YL)QUINOLIN 2(1H) ONE; 4-AMINO-5-FLUORO-3-(5-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL)QUINOLIN-2(1H)-ONE; BCAR1 PROTEIN, HUMAN; BENZIMIDAZOLE DERIVATIVE; MONOCROTALINE; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; HYPOXIA; LUNG ARTERY; LUNG ENDOTHELIUM; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; ANIMAL; CASE CONTROL STUDY; DISEASE MODEL; ENDOTHELIUM CELL; METABOLISM; MOUSE; PHYSIOLOGY; PULMONARY ARTERY;

ANIMALS; BENZIMIDAZOLES; CASE-CONTROL STUDIES; CRK-ASSOCIATED SUBSTRATE PROTEIN; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; HUMANS; HYPERTENSION, PULMONARY; MICE; MONOCROTALINE; MYOCYTES, SMOOTH MUSCLE; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PULMONARY ARTERY; PYRIMIDINES; QUINAZOLINES; QUINOLONES; RATS; SIGNAL TRANSDUCTION;

EID: 84867131487     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201202-0309OC     Document Type: Article

References (49)

1. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-163.
2. Humbert M, Sitbon O, Yaici A, Montani D, O'Callaghan DS, Jais X, Parent F, Savale L, Natali D, Gunther S, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36:549-555.
3. Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:558-564.
4. Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, Zadigue P, Dartevelle P, Simonneau G, Adnot S, Maitre B, et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 2009;119:512-523.
5. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 2005;112:423-431. (Pubitemid 41022085)
6. Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, Mazmanian M, Fadel E, Mussot S, Mercier O, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:81-88. (Pubitemid 351919196)
7. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-2821. (Pubitemid 41434408)
8. Tu L, Dewachter L, Gore B, Fadel E, Dartevelle P, Simonneau G, Humbert M, Eddahibi S, Guignabert C. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45:311-322.
9. Cabodi S, Tinnirello A, Di Stefano P, Bisaro B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, et al. P130cas as a new regulator of mammary epithelial cell proliferation, survival, and Her2- neu oncogene-dependent breast tumorigenesis. Cancer Res 2006;66:4672-4680.
10. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, Defilippi P. Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 2010;10:858-870.
11. Korah R, Choi L, Barrios J, Wieder R. Expression of FGF-2 alters focal adhesion dynamics in migration-restricted mda-mb-231 breast cancer cells. Breast Cancer Res Treat 2004;88:17-28. (Pubitemid 39524441)
12. Ojaniemi M, Vuori K. Epidermal growth factor modulates tyrosine phosphorylation of p130cas: involvement of phosphatidylinositol 39-kinase and actin cytoskeleton. J Biol Chem 1997;272:25993-25998. (Pubitemid 27438927)
13. Pellet-Many C, Frankel P, Evans IM, Herzog B, Junemann-Ramirez M, Zachary IC. Neuropilin-1 mediates pdgf stimulation of vascular smooth muscle cell migration and signalling via p130cas. Biochem J 2011;435:609-618.
14. Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D, Hamon M, Adnot S, Eddahibi S. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005;111:2812-2819. (Pubitemid 40791554)
15. El-Bizri N, Guignabert C, Wang L, Cheng A, Stankunas K, Chang CP, Mishina Y, Rabinovitch M. Sm22alpha-targeted deletion of bone morphogenetic protein receptor 1a in mice impairs cardiac and vascular development, and influences organogenesis. Development 2008;135:2981-2991.
16. Guignabert C, Tu L, Izikki M, Dewachter L, Zadigue P, Humbert M, Adnot S, Fadel E, Eddahibi S. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with sm22alpha-targeted overexpression of the serotonin transporter. FASEB J 2009;23:4135-4147.
17. Dahal BK, Cornitescu T, Tretyn A, Pullamsetti SS, Kosanovic D, Dumitrascu R, Ghofrani HA, Weissmann N, Voswinckel R, Banat GA, et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. AmJ Respir Crit Care Med 2010;181:158-167.
18. Azab AK, Azab F, Quang P, Maiso P, Sacco A, Ngo HT, Liu Y, Zhang Y, Morgan BL, Roccaro AM, Ghobrial IM. FGFR3 is overexpressed Waldenström macroglobulinemia and its inhibition by dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clin Cancer Res 2011;17:4389-4399.
19. Guignabert C, Alvira CM, Alastalo TP, Sawada H, Hansmann G, Zhao M, Wang L, El-Bizri N, Rabinovitch M. Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta- dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol 2009;297:L1082-L1090.
20. Guignabert C, Izikki M, Tu LI, Li Z, Zadigue P, Barlier-Mur AM, Hanoun N, Rodman D, Hamon M, Adnot S, et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 2006;98:1323-1330. (Pubitemid 43948088)
21. Raines EW. Pdgf and cardiovascular disease. Cytokine Growth Factor Rev 2004;15:237-254. (Pubitemid 38781049)
22. Lepetit H, Eddahibi S, Fadel E, Frisdal E, Munaut C, Noel A, Humbert M, Adnot S, D'Ortho MP, Lafuma C. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J 2005;25:834-842. (Pubitemid 40667681)
23. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by erbb/her receptors. Int J Radiat Oncol Biol Phys 2004;58:903-913. (Pubitemid 38221150)
24. Nam NH, Parang K. Current targets for anticancer drug discovery. Curr Drug Targets 2003;4:159-179. (Pubitemid 36553587)
25. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010;182:1171-1177.
26. Defilippi P, Di Stefano P, Cabodi S. P130cas: a versatile scaffold in signaling networks. Trends Cell Biol 2006;16:257-263. (Pubitemid 43728873)
27. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H, Yazaki Y, Hirai H. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J 1994;13:3748-3756. (Pubitemid 24275020)
28. Ruest PJ, Shin NY, Polte TR, Zhang X, Hanks SK. Mechanisms of cas substrate domain tyrosine phosphorylation by FAK and Src. Mol Cell Biol 2001;21:7641-7652. (Pubitemid 32988775)
29. Amabile N, Heiss C, Real WM, Minasi P, McGlothlin D, Rame EJ, Grossman W, De Marco T, Yeghiazarians Y. Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. Am J Respir Crit Care Med 2008;177:1268-1275. (Pubitemid 351860937)
30. Deng B, Huang W, Tan QY, Fan XQ, Jiang YG, Liu L, Zhong YY, Liang YG, Wang RW. Breast cancer anti-estrogen resistance protein 1 (BCAR1/p130cas) in pulmonary disease tissue and serum. Mol Diagn Ther 2011;15:31-40.
31. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 2009;119:252-266.
32. Cabodi S, Tinnirello A, Bisaro B, Tornillo G, del Pilar Camacho-Leal M, Forni G, Cojoca R, Iezzi M, Amici A, Montani M, et al. P130cas is an essential transducer element in erbb2 transformation. FASEB J 2010;24:3796-3808.
33. Ta HQ, Thomas KS, Schrecengost RS, Bouton AH. A novel association between p130cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells. Cancer Res 2008;68:8796-8804.
34. van der Flier S, Brinkman A, Look MP, Kok EM, Meijer-van Gelder ME, Klijn JG, Dorssers LC, Foekens JA. BCAR1/p130cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst 2000;92:120-127. (Pubitemid 30089868)
35. Dorssers LC, Grebenchtchikov N, Brinkman A, Look MP, van Broekhoven SP, de Jong D, Peters HA, Portengen H, Meijer-van Gelder ME, Klijn JG, van Tienoven DT, Geurts-Moespot A, Span PN, Foekens JA, Sweep FC. The prognostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res 2004;10:6194-6202. (Pubitemid 39287526)
36. Cabodi S, Moro L, Baj G, Smeriglio M, Di Stefano P, Gippone S, Surico N, Silengo L, Turco E, Tarone G, et al. P130cas interacts with estrogen receptor alpha and modulates non-genomic estrogen signaling in breast cancer cells. J Cell Sci 2004;117:1603-1611. (Pubitemid 38559834)
37. Dorssers LC, van Agthoven T, Brinkman A, Veldscholte J, Smid M, Dechering KJ. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway. Breast Cancer Res 2005;7:R82-R92.
38. Riggins RB, Thomas KS, Ta HQ, Wen J, Davis RJ, Schuh NR, Donelan SS, Owen KA, Gibson MA, Shupnik MA, et al. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 2006;66:7007-7015. (Pubitemid 44197676)
39. Oda Y, Renaux B, Bjorge J, Saifeddine M, Fujita DJ, Hollenberg MD. Csrc is a major cytosolic tyrosine kinase in vascular tissue. Can J Physiol Pharmacol 1999;77:606-617.
40. Courboulin A, Paulin R, Giguere NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Cote J, et al. Role for mir-204 in human pulmonary arterial hypertension. J ExpMed 2011;208:535-548.
41. Honda H, Oda H, Nakamoto T, Honda Z, Sakai R, Suzuki T, Saito T, Nakamura K, Nakao K, Ishikawa T, et al. Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130cas. Nat Genet 1998;19:361-365. (Pubitemid 28357908)
42. Shin NY, Dise RS, Schneider-Mergener J, Ritchie MD, Kilkenny DM, Hanks SK. Subsets of the major tyrosine phosphorylation sites in Crk-associated substrate (Cas) are sufficient to promote cell migration. J Biol Chem 2004;279:38331-38337. (Pubitemid 39295981)
43. Cho SY, Klemke RL. Extracellular-regulated kinase activation and cas/ crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix. J Cell Biol 2000;149:223-236. (Pubitemid 30196711)
44. Chodniewicz D, Klemke RL. Regulation of integrin-mediated cellular responses through assembly of a cas/crk scaffold. Biochim Biophys Acta 2004;1692:63-76.
45. Holcomb M, Rufini A, Barila D, Klemke RL. Deregulation of proteasome function induces abl-mediated cell death by uncoupling p130cas and c-CrkII. J Biol Chem 2006;281:2430-2440. (Pubitemid 43845702)
46. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54:S10-S19.
47. Kim W, Seok Kang Y, Soo Kim J, Shin NY, Hanks SK, Song WK. The integrin-coupled signaling adaptor p130cas suppresses smad3 function in transforming growth factor-beta signaling. Mol Biol Cell 2008;19:2135-2146.
48. Wendt MK, Smith JA, Schiemann WP. P130cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of smad2/3 activity. J Biol Chem 2009;284:34145-34156.
49. Nasim MT, Ogo T, Chowdhury HM, Zhao L, Chen CN, Rhodes C, Trembath RC. Bmpr-ii deficiency elicits pro-proliferative and antiapoptotic responses through the activation of TGFbeta-tak1-mapk pathways in pah. Hum Mol Genet 2012;21:2548-2558.